Search

Your search keyword '"Gravalos C"' showing total 74 results
Start Over Author "Gravalos C"
74 results on '"Gravalos C"'

1. Safety and efficacy of encorafenib–cetuximab combination in BRAFV600E-mutated metastatic colorectal cancer: real-world evidence from the CONFIDENCE Spanish multicenter study

Author

Fernández-Montes, A., Ros, J., García-Alfonso, P., Graña, B., Brozos-Vázquez, E., Melián, M., Jiménez-Gordo, A.M<ce:sup loc='post">ª</ce:sup>, Martínez de Castro, E., Busquier, I., Ferrández Arias, A., Grávalos, C., Covela, M., Ruíz-Casado, A., González-Flores, E., Safont, M<ce:sup loc='post">ª</ce:sup> J., Cano, J.M<ce:sup loc='post">ª</ce:sup>, Alonso-López, C., Gómez-Reina, M<ce:sup loc='post">ª</ce:sup> J., Donnay, O., Manzano-Mozo, J.L., Sampedro Domarco, P., Falcó, E., Rodríguez, N., García-Benito, C., and Aranda, E.

Published
2024
Full Text
View/download PDF

2. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

Author

Toledano-Fonseca, M., Gómez-España, M.A., Élez, E., Grávalos, C., García-Alfonso, P., Rodríguez, R., Losa, F., Alés Díaz, I., Graña, B., Valladares-Ayerbes, M., García-Ortiz, M.V., Polo, E., Salgado, M., Rivera, F., Safont, M.J., Salud, A., Ruiz-Casado, A., Tabernero, J.M., Riesco, M.C., Rodríguez-Ariza, A., and Aranda, E.

Published
2023
Full Text
View/download PDF

3. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

Author

Tabernero, Josep, Argilés, Guillem, Falcone, Alfredo, Ciardiello, Fortunato, Goldberg, Richard, Bennouna, Jaafar, Argilés, Tabernero, J., Mulet, N., Limón, M.L., Valladares, M., Jiménez, P., Vieitez, J. M<ce:sup loc='post">a</ce:sup>, Grávalos, C., García-Alfonso, P., Santos, C., Páez, D., Tobeña, M., Sastre, J., García Paredes, B., Benavides, M., Aranda, E., Cano, M.T., Loupakis, F., Rguez Garrote, M., Guillén, C., Rivera, Ma F., Safont, J., Hiret, S., Bennouna, J., Pannier, D., Malka, D., Falcone, A., Cremolini, C., Mulet, Nuria, Valladares-Ayerbes, Manuel, Viéitez, José M., Grávalos, Cristina, García-Alfonso, Pilar, Santos, Cristina, Tobeña, María, García-Paredes, Beatriz, Benavides, Manuel, Cano, María T., Loupakis, Fotios, Rodríguez-Garrote, Mercedes, Rivera, Fernando, Goldberg, Richard M., Cremolini, Chiara, Tabernero, Josep M., and Aranda, Enrique

Published
2022
Full Text
View/download PDF

4. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and

Author

Viéitez, J.M., Jiménez, P., Aguilar, E. Aranda, Gómez, A., Gil Calle, S., Salud, A., Valladares, M., Graña, B., García-Alfonso, P., Rivera, F., Quintero, G., Reina, J.J., González Flores, E., Salgado, M., Grande, E., Guillén, C., Garcia Carbonero, R., Flor, M.J., Safont, M.J., La Casta, A., Arévalo, S., Sastre, J., López López, R., Manzano, H., Guillot, M., Hernández Yagüe, X., Arrivi, A., Falcó, E., Gallego, J., Escudero, P., Cabezas, I., Juárez, A., Gálvez, E., Grávalos, C., Robles, L., Polo, E., Dueñas, R., Campos, J.M., Albert, A., Salinas, P., Montagut, C., Provencio, M., Ruiz Casado, A., Muñoz, J., Gil Raga, M., Chilet, M.R., González González, F.J., Massutí, B., López, A., Aparicio, J., Marín, M., Alfaro, J., Zanui, M., Gutiérrez Abad, D., García Tapiador, A.M., García-Girón, C., Molina Saera, J., Torres Sánchez, E., López, I., Bosch, C., Valero, J., Martínez de Prado, P., Cano, M.T., Reina-Zoilo, J.J., Salud-Salvia, A., Robles-Díaz, L., Gil, S., Asensio-Martínez, E., García-Paredes, B., López, R.L., Valladares-Ayerbes, M., Aranda, E., and Díaz-Rubio, E.

Published
2021
Full Text
View/download PDF

7. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

Author

Aranda, E., García-Alfonso, P., Benavides, M., Sánchez Ruiz, A., Guillén-Ponce, C., Safont, M.J., Alcaide, J., Gómez, A., López, R., Manzano, J.L., Méndez Ureña, M., Sastre, J., Rivera, F., Grávalos, C., García, T., Martín-Valadés, J.I., Falcó, E., Navalón, M., González Flores, E., M<ce:sup loc='post">a</ce:sup> García Tapiador, A., M<ce:sup loc='post">a</ce:sup> López Muñoz, A., Barrajón, E., Reboredo, M., García Teijido, P., Viudez, A., Cárdenas, N., and Díaz-Rubio, E.

Published
2018
Full Text
View/download PDF

10. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

Author

Garcia-Alfonso P, Diaz-Rubio E, Abad A, Carrato A, Massuti B, Ortiz-Morales M, Mozo J, Munoz A, Duran G, Sastre J, Safont M, Ferreiro R, Rivera F, Gonzalez E, Valladares-Ayerbes M, Gravalos C, Alonso-Orduna V, Vieitez J, Yubero A, Aranda E, and Spanish Cooperative Grp Treatment

Abstract

Background Biologicals, in combination with chemotherapy, are recommended as first-line treatment of metastatic colorectal cancer (mCRC); however, evidence guiding the appropriate management of older patients with mCRC is limited. Objective This study was undertaken to compare the efficacy and safety outcomes in older versus younger patients with mCRC who received first-line biological therapy. Methods This retrospective analysis used pooled data from five trials undertaken by the Spanish Cooperative Group for the Treatment of Digestive Tumours. All were studies of adults with advanced CRC who received first-line treatment with chemotherapy plus bevacizumab, cetuximab or panitumumab, stratified by age (>= 65 vs. < 65 years). Endpoints included progression-free survival (PFS), overall survival (OS), overall response rate (ORR) and safety. Results In total, 999 patients from five studies were included in the analysis: 480 (48%) were aged >= 65 years, and 519 (52%) were aged < 65 years. Median PFS did not differ significantly between patients aged >= 65 and < 65 years (9.9 vs. 9.4 months; hazard ratio [HR] 1.01; 95% confidence interval [CI] 0.88-1.17). Median OS was significantly shorter in older than in younger patients (21.3 vs. 25.0 months; HR 1.21; 95% CI 1.04-1.41). There was no significant difference between older and younger patients in ORR (59 vs. 62%). Patients aged >= 65 years experienced significantly more treatment-related grade 3 or higher adverse events (61.67%) than did patients aged < 65 years (45.86%). Conclusions Biologicals plus chemotherapy is an effective first-line treatment option for selected patients aged >= 65 years with mCRC and has a manageable safety profile and efficacy comparable to that observed in younger patients.

Published
2021

13. Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results

Author

Salazar R, Capdevila J, Luis Manzano J, Pericay C, Martinez-Villacampa M, Lopez C, Losa F, Jose Safont M, Gomez-Espana A, Alonso-Orduna V, Escudero P, Gallego J, Garcia-Paredes B, Palacios A, Biondo S, Gravalos C, and Aranda E

Subjects
Bevacizumab, Chemoradiotherapy, Neoadjuvant, Locally-advanced rectal cancer
Abstract

BackgroundPreoperative chemoradiotherapy with capecitabine is considered as a standard of care for locally advanced rectal cancer. The "Tratamiento de Tumores Digestivos" group (TTD) previously reported in a randomized Ph II study that the addition of Bevacizumab to capecitabine-RT conferred no differences in the pre-defined efficacy endpoint (pathological complete response).We present the follow-up results of progression-free survival, distant relapse-free survival, and overall survival data at 3 and 5years.MethodsPatients (pts) were randomized to receive 5weeks of radiotherapy (45Gy/25 fractions) with concurrent Capecitabine 825mg/m2 twice daily, 5days per week with (arm A) or without (arm b) bevacizumab (5mg/kg once every 2weeks).ResultsIn our study, the addition of bevacizumab to capecitabine and radiotherapy in the neoadjuvant setting shows no differences in pathological complete response (15.9% vs 10.9%), distant relapse-free survival (81.0 vs 80.4 and 76.2% vs 78.2% at 3 and 5years respectively), disease-free survival (75% vs 71.7 and 68.1% vs 69.57% at 3 and 5years respectively) nor overall survival at 5-years of follow-up (81.8% vs 86.9%).Conclusionsthe addition of bevacizumab to capecitabine plus radiotherapy does not confer statistically significant advantages neither in distant relapse-free survival nor in disease-free survival nor in Overall Survival in the short or long term.Trial registrationEudraCT number: 2009-010192-24.Clinicaltrials.gov number: NCT01043484.

Published
2020

15. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings†

Author

Kubicka, S., Greil, R., André, T., Bennouna, J., Sastre, J., Van Cutsem, E., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., Makrutzki, M., Arnold, D., Andel, J, Balcke, P, Benedicic, B, Eisterer, W, Fridrik, M, Jagdt, B, Keil, F, Kretschmer, A, Krippl, P, Oexle, H, Pecherstorfer, M, Samonigg, H, Schmid, M, Thaler, J, Tinchon, C, Weiss, H., Arts, J, De Man, M, Demolin, G, Janssens, J, Polus, M., Benczikova, B, Melichar, B, Prausova, J, Vitek, P., Andersen, FZ, Jensen, BB, Keldsen, N, Østerlind, K, Vistisen, K., Elme, A, Magi, A, Ojamaa, K., Ristamäki, R, Salminen, T., Ben Abdelghani, M, Bouche, O, Borg, C, Bouhier-Leporrier, K, Breysacher, G, Chone, L, Clavero Fabri, M-C, Deplanque, G, Desseigne, F, Dourthe, L-M, Ezenfis, J, Faroux, R, François, E, Garnier, C, Gaspard, M-H, Hebbar, M, Illory, JF, Kaminsky, M-C, Lecomte, T, Legoux, J-L, Levache, B, Lobry, C, Lotz, J-P, Mabro, M, Manet-Lacombe, S, Manfredi, S, Matysiak Budnik, T, Miglianico, L, Mineur, L, Moullet, I, Naman, H, Nouyrigat, P, Oziel-Taieb, S, Perrier, H, Pezet, D, Philip, J, Pottier, V, Porneuf, M, Ramdani, M, Re, D, Rinaldi, Y, Spaeth, D, Taieb, J, Terrebonne, E, Texereau, P, Thirot Bidault, A, Tournigand, C, Tubiana-Mathieu, N, Vantelon, J-M, Viret, F, Ychou, M., Bangerter, M, Bertram, ME, Bohnsteen, B, Brinkmann, L, Caca, K, Constantin, C, Cordes, H-J, Dietrich, G, Eggert, J, Engel, E, Fahlke, J, Fensterer, H, Florschütz, A, Folprecht, G, Forstbauer, H, Freier, W, Freund, M, Frickhofen, N, Gäbele, E, Geiler, M, Gieseler, F, Göhler, T, Graeven, U, Groschek, M, Grundeis, M, Hacker, U, Hagen, V, Hebart, HF, Hegewisch-Becker, S, Heike, M, Herrmann, T, Hildebrandt, B, Höffkes, H-G, Hübner, G, Hübner, J, Kettner, E, Kneba, M, Kohnke, JW, Kojouharoff, G, König, C, Kretzschmar, A, Kröning, H, Kürner, K, Lammert, F, Lerchenmüller, C, Lück, A, Meiler, J, Mergenthaler, H-G, Müller, L, Müller-Naendrup, C, Nusch, A, Papke, J, Porschen, R, Rädle, J, Reddemann, C, Ridwelski, K, Riera-Knorrenschild, J, Rudi, J, Schmalenberger, A, Schimanski, C-C, Schlegel, F, Schlichting, C, Schmidt, P, Schmiegel, W, Schmitz, S, Schulze-Bergkamen, H, Schwaner, I, Schwarzer, A, Schwerdtfeger, M, Selbach, J, Sieber, M, Siebler, J, Staib, P, Stauch, M, Steffens, C-C, Stübs, P, Tischendorf, J, Trarbach, T, Tummes, D, Valdix, A-R, Vogel, A, Von Wichert, GPL, Walther, M, Welslau, W, Wilhelm, G, Wobster, H, Wolf, T, Zeigenhagen, N, Zomorodbaksch, B., Batman, E, Bloemendal, HJ, Kehrer, DFS., Guren, T, Indrebø, G, Kersten, C, Soerbye, H., Fragoso, M, Fragoso, R, Mellidez, JC, Sa, A., Aljobran, A, Darwish, T., Alonso-Orduna, V, Aparicio, J, Aranda, E, Bosch, C, Galan-Brotons, A, Busquier Hernandez, I, Camara, JC, Campos Cervera, JM, Carlos Garcia Giron, C, Del Prado, PM, Donnay, O, Escudero, P, Falco, E, Gallego Plazas, J, Garcia Alfonso, P, Gonzalez Flores, E, Gravalos, C, Guardeno, R, Juárez, A, Lopez Ladron, A, Losa Gaspa, F, MVicent Vergé, J, Marcuello Gaspar, E, Massuti Sureda, B, Molina, J, Montero, IC, Muñoa, AL, Naranjo, MB, Oruezabal Moreno, MJ, Pachón Olmos, V, Pericay, C, Reina Zoilo, JJ, Rivera, F, Ruiz Casado, A, Safont, MJ, Salud Salvia, A, Tobena, M, Toral, JC, Valenti, V, Valladares Ayerbes, M, Vieitez, JM, Vera, R, Vieitez, JM., Berglund, A, Fernebro, E., Hess-Umbricht, V, Pless, M, Popescu, R, and Winterhalder, R.

Published
2013
Full Text
View/download PDF

18. Phase II randomized trial of capecitabine 1 radiation therapy with/without bevacizumab as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: Final results of 3 and 5-year disease free survival, distant relapse free survival and overall survival

Author

Gravalos, C., Capdevila, J., Layos, L., Pericay, C., Martinez-Villacampa, M., Lopez Lopez, C., Losa, F., Safont, M. J., Gomez-Espana, A., Alonso, V., Escudero, P., Javier gallego, Garcia-Paredes, B., Palacios, A., Biondo, S., Salazar, R., and Aranda Aguilar, E.

Published
2017

21. Benefits of upfront primary tumour resection (UPTR) according to sidedness in mCRC: Retrospective analyses of TTD MACRO-2 and PLANET randomised trials

Author

Benavides, M., primary, Abad, A., additional, Carrato, A., additional, Gravalos, C., additional, Fernández-Montes, A., additional, Falcó, E., additional, González-Flores, E., additional, Garcia Garcia, T., additional, Martin-Valades, J.I., additional, Gallego Plazas, J., additional, Valladares-Ayerbes, M., additional, García-Girón, C., additional, Dueñas, R., additional, García-Tapiador, A., additional, Pericay, C., additional, Losa, F., additional, Viudez, A., additional, García-Teijido, P., additional, Diaz Rubio, E., additional, and Aranda Aguilar, E., additional

Published
2017
Full Text
View/download PDF

22. A randomized Phase 2 study comparing different dosing approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients

Author

Argilés Martinez, G., primary, Sanz-Garcia, E., additional, Valladares-Ayerbes, M., additional, Viéitez, J.M., additional, Garcia-Alfonso, P., additional, Gravalos, C., additional, Tobeña, M., additional, Duran Ogaya, G., additional, Cano Osuna, M.T., additional, García-Paredes, B., additional, Santos, C., additional, Rodríguez-Garrote, M., additional, Rivera Herrero, F., additional, Safont, M.J., additional, Falcone, A., additional, Ciardiello, F., additional, Goldberg, R., additional, Bennouna, J., additional, Tabernero, J., additional, and Aranda Aguilar, E., additional

Published
2017
Full Text
View/download PDF

23. Impact of tumor location on the efficacy of first-line anti-EGFR monoclonal antibody plus chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC): Retrospective analyses of the randomized MACRO-2 and PLANET trials from TTD Group

Author

Benavides, M., primary, Carrato, A., additional, Abad, A., additional, Guillen-Ponce, C., additional, Garcia-Alfonso, P., additional, Gil, S., additional, Cano Osuna, M.T., additional, Safont, M.J., additional, Gravalos, C., additional, Manzano-Mozo, J.L., additional, Sanchez, A., additional, Alcaide-Garcia, J., additional, López, R., additional, Massuti Sureda, B., additional, Sastre, J., additional, Martinez de Castro, E., additional, Escudero, P., additional, Méndez-Ureña, M., additional, Diaz Rubio, E., additional, and Aranda Aguilar, E., additional

Published
2017
Full Text
View/download PDF

24. Phase II randomized trial of capecitabine + radiation therapy with/without bevacizumab as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: Final results of 3 and 5-year disease free survival, distant relapse free survival and overall survival

Author

Gravalos, C., primary, Capdevila, J., additional, Layos, L., additional, Pericay, C., additional, Martínez-Villacampa, M., additional, López López, C., additional, Losa, F., additional, Safont, M.J., additional, Gómez-España, A., additional, Alonso, V., additional, Escudero, P., additional, Gallego, J., additional, García-Paredes, B., additional, Palacios, A., additional, Biondo, S., additional, Salazar, R., additional, and Aranda Aguilar, E., additional

Published
2017
Full Text
View/download PDF

25. 585P - POLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers

Author

Fernandez, M E Elez, Gómez-España, M.A., Grávalos, C., García-Alfonso, P., Rodríguez, B., Losa, F., Ales-Diaz, I.C., Suarez, B Graña, Toledano, M., Valladares-Ayerbes, M., Marques, E Polo, Fernandez, M Salgado, de Castro, E Martínez, Raga, M Gil, Salvia, M A Salud, Ruiz-Casado, A., Rodríguez-Ariza, A., and Aguilar, E Aranda

Published
2019
Full Text
View/download PDF

26. Phase II clinical trial with axitinib as maintenance therapy in patients (p) with metastatic colorectal carcinoma (CRC)

Author

Gravalos, C., primary, Carrato, A., additional, Tobeña, M., additional, Pulido, E. Grande, additional, Soler, G., additional, Vieitez, J., additional, Robles, L., additional, Valladares-Ayerbes, M., additional, Polo, E., additional, Limon, M.L., additional, Safont, M.J., additional, Lopez, C., additional, Alfonso, P. García, additional, and Aranda, E., additional

Published
2016
Full Text
View/download PDF

27. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

Author

Longo-Muñoz, F., primary, Argiles, G., additional, Tabernero, J., additional, Cervantes, A., additional, Gravalos, C., additional, Pericay, C., additional, Gil-Calle, S., additional, Mizuguchi, H., additional, Carrato-Mena, A., additional, Limón, M. L., additional, and Garcia-Carbonero, R., additional

Published
2016
Full Text
View/download PDF

28. O-006 - Ultra-selection of metastatic colorectal cancer patients using next generation sequencing platform to improve clinical efficacy of anti-EGFR therapy

Author

Vidal, J., Dalmeses, A., Vivas, C. Santos, Garcia-Carbonero, R., García-Alfonso, P., Carrato, A., Elez, E., Ortiz, M., Losa, F., Massutí, B., Valladares-Ayerbes, M., Manzano, J., de Prado, J. Vieitez, Gallego, J., Grávalos, C., Varela, M., Azuara, D., Tabernero, J., Salazar, R., Aranda, E., Bellosillo, B., and Montagut, C.

Published
2018
Full Text
View/download PDF

29. 2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC)

Author

Shinozaki, E., primary, Laurent, S., additional, Gravalos, C., additional, Benavides, M., additional, Munoz, F. Longo, additional, Mizuguchi, H., additional, Wahba, M., additional, Ychou, M., additional, Ciardiello, F., additional, Siena, S., additional, Yamaguchi, K., additional, Muro, K., additional, Denda, T., additional, Tsuji, Y, additional, Loehrer, P, additional, Lenz, H.J., additional, Tebbutt, N., additional, Mayer, R.J., additional, Van Cutsem, E., additional, and Ohtsu, A., additional

Published
2015
Full Text
View/download PDF

30. 2128 Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)

Author

Abad, A., primary, Massuti, B., additional, Gravalos, C., additional, Escudero, P, additional, Guillen-Ponce, C., additional, Manzano, J.L., additional, Ortiz, M.J., additional, Safont, M.J., additional, Gallego, J., additional, Sastre, J., additional, Pericay, C., additional, Duenas, R., additional, Rivera, F., additional, Losa, F., additional, Valladares-Ayerbes, M., additional, Gonzalez, E., additional, Robles, L., additional, Aranda, E., additional, and Carrato, A., additional

Published
2015
Full Text
View/download PDF

31. O-010 KRAS and BRAF gene subgroup analysis in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients with metastatic colorectal cancer

Author

Hochster, H., primary, Hager, S., additional, Pipas, J.M., additional, Tebbutt, N., additional, Laurent, S., additional, Gravalos, C., additional, Benavides, M., additional, Longo Munoz, F., additional, Portales, F., additional, Ciardiello, F., additional, Siena, S., additional, Yamaguchi, K., additional, Muro, K., additional, Denda, T., additional, Tsuji, Y., additional, Ohtsu, A., additional, Van Cutsem, E., additional, and Mayer, R.J., additional

Published
2015
Full Text
View/download PDF

32. 610TiP - A randomized Phase 2 study comparing different dosing approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients

Author

Argilés Martinez, G., Sanz-Garcia, E., Valladares-Ayerbes, M., Viéitez, J.M., Garcia-Alfonso, P., Gravalos, C., Tobeña, M., Duran Ogaya, G., Cano Osuna, M.T., García-Paredes, B., Santos, C., Rodríguez-Garrote, M., Rivera Herrero, F., Safont, M.J., Falcone, A., Ciardiello, F., Goldberg, R., Bennouna, J., Tabernero, J., and Aranda Aguilar, E.

Published
2017
Full Text
View/download PDF

33. 583P - Impact of tumor location on the efficacy of first-line anti-EGFR monoclonal antibody plus chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC): Retrospective analyses of the randomized MACRO-2 and PLANET trials from TTD Group

Author

Benavides, M., Carrato, A., Abad, A., Guillen-Ponce, C., Garcia-Alfonso, P., Gil, S., Cano Osuna, M.T., Safont, M.J., Gravalos, C., Manzano-Mozo, J.L., Sanchez, A., Alcaide-Garcia, J., López, R., Massuti Sureda, B., Sastre, J., Martinez de Castro, E., Escudero, P., Méndez-Ureña, M., Diaz Rubio, E., and Aranda Aguilar, E.

Published
2017
Full Text
View/download PDF

34. 492P - Benefits of upfront primary tumour resection (UPTR) according to sidedness in mCRC: Retrospective analyses of TTD MACRO-2 and PLANET randomised trials

Author

Benavides, M., Abad, A., Carrato, A., Gravalos, C., Fernández-Montes, A., Falcó, E., González-Flores, E., Garcia Garcia, T., Martin-Valades, J.I., Gallego Plazas, J., Valladares-Ayerbes, M., García-Girón, C., Dueñas, R., García-Tapiador, A., Pericay, C., Losa, F., Viudez, A., García-Teijido, P., Diaz Rubio, E., and Aranda Aguilar, E.

Published
2017
Full Text
View/download PDF

35. 508P - Phase II randomized trial of capecitabine + radiation therapy with/without bevacizumab as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: Final results of 3 and 5-year disease free survival, distant relapse free survival and overall survival

Author

Gravalos, C., Capdevila, J., Layos, L., Pericay, C., Martínez-Villacampa, M., López López, C., Losa, F., Safont, M.J., Gómez-España, A., Alonso, V., Escudero, P., Gallego, J., García-Paredes, B., Palacios, A., Biondo, S., Salazar, R., and Aranda Aguilar, E.

Published
2017
Full Text
View/download PDF

37. 6653 Exploratory study of the subcutaneous fat gene expression profile in patients with metastatic pancreatic carcinoma treated with standard gemcitabine chemotherapy regimen

Author

Sobrino, J.A. Nuñez, primary, Castellano, D., additional, Cervera, R. Cubedo, additional, Garcia-Lopez, J., additional, Gravalos, C., additional, Sepulveda, J.A., additional, Cañete, I. Ghanem, additional, Escobar, I. Garcia, additional, Gomez-Sanz, R., additional, and Cortes-Funes, H., additional

Published
2009
Full Text
View/download PDF

38. 4004 Cetuximab plus capecitabine as first-line treatment for elderly patients (pts) with advanced colorectal cancer (mCRC). Final analysis of activity and survival according to KRAS status – the TTD-06–01 Spanish Cooperative Group trial

Author

Rivera, F., primary, Gravalos, C., additional, Massutí, B., additional, Puente, J., additional, Marcuello, E., additional, Valladares, M., additional, Gutiérrez, V., additional, Layos, L., additional, Díaz-Rubio, E., additional, and Aranda, E., additional

Published
2009
Full Text
View/download PDF

44. Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (MCRC) treated with single-agent cetuximab as first-line treatment

Author

Gravalos, C., primary, Sastre, J., additional, Aranda, E., additional, Massutí, B., additional, Vega-Villegas, M. E., additional, Gómez, A., additional, Varella-Garcia, M., additional, Jimeno, A., additional, Díaz- Rubio, E., additional, and Hidalgo, M., additional

Published
2007
Full Text
View/download PDF

48. 551P - Ras Analysis of the Planet Study: Phase Ii Trial of Panitumumab (P) Plus Folfox4 or Folfiri in Subjects with Wild-Type (Wt) Kras Colorectal Cancer (Crc) and Liver-Limited Disease (Lld)

Author

Abad, A., Sureda, B. Massuti, Grávalos, C., Escudero, P., Guillen-Ponce, C., Gómez, A., Safont, M.J., Plazas, J. Gallego, Sastre, J., Pericay, C., Dueñas, R., López, C., Losa, F., Valladares-Ayerbes, M., Flores, E. González, Díaz, L. Robles, Layos, L., Carrato, A., and Aranda, E.

Published
2014
Full Text
View/download PDF

49. 499O - Phase Ii Study of First-Line Mfolfox Plus Cetuximab (C) for 8 Cycles Followed By Mfolfox Plus C or Single Agent (S/A) C As Maintenance Therapy in Patients (P) with Metastatic Colorectal Cancer (Mcrc): the Macro-2 Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [Ttd])

Author

Alfonso, P. García, Benavides, M., Ruiz, A. Sánchez, Guillen-Ponce, C., Safont, M.J., Alcaide, J., Gómez, A., Lopez, R., Manzano, J.L., Urena, M. Mendez, Rivera, F., Sastre, J., Grávalos, C., García, T. García, Martin-Valades, J.I., Falco, E., Flores, E. González, Navalón, M., Rubio, E. Diaz, and Aranda, E.

Published
2014
Full Text
View/download PDF

50. PD-0006 - Panitumumab Plus FOLFOX4 or Panitumumab Plus Folfiri in Subjects with Wild-Type KRAS (EXON 2) Colorectal Cancer and Multiple or Unresectable Liver-Limited Metastases: Data from the Randomized, Phase II Planet Study

Author

Abad, A., Massutí, B., Grávalos, C., Escudero, P., Guillén-Ponce, C., Layos, L., Gomez, M.A., Safont, M.J., Gallego, J., Sastre, J., Pericay, C., Dueñas, R., López-López, C., Losa, F., Valladares, M., González-Flores, E., Yuste, A., Robles, L., Sáenz, A., Cano, T., Carrato, A., and Aranda, E.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results